VCYT (Veracyte) LT-Debt-to-Total-Asset : 0.03 (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Veracyte LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Veracyte's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.03.

Veracyte's long-term debt to total assets ratio increased from Dec. 2023 (0.01) to Dec. 2024 (0.03). It may suggest that Veracyte is progressively becoming more dependent on debt to grow their business.

Veracyte LT-Debt-to-Total-Asset Historical Data

The historical data trend for Veracyte's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veracyte LT-Debt-to-Total-Asset Chart

Veracyte Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.01

0.03

Veracyte Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.03

Veracyte LT-Debt-to-Total-Asset Calculation

Veracyte's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	43.237	/	1300.035
	=	0.03

Veracyte's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	43.237	/	1300.035
	=	0.03

Veracyte (NAS:VCYT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Veracyte LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Veracyte's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Veracyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (NAS:VCYT) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

12V:Germany

Address

6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.veracyte.com

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

Executives

John Leite	officer: Chief Commercial Officer-CLIA	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Phillip G. Febbo	officer: Chief Scientific & Med Officer	C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Marc Stapley	officer: Chief Executive Officer	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Annie Mcguire	officer: SVP, General Counsel	C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Rebecca Chambers	officer: Chief Financial Officer	3052 ORCHARD DR., SAN JOSE CA 95134
Karin Eastham	director	C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Jonathan Wygant	officer: VP, Chief Accounting Officer	3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Robert S Epstein	director
Evan/ Fa Jones	director	C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Jens Holstein	director	C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John L Bishop	director
Bonnie H Anderson	director, officer: President & CEO	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Giulia C Kennedy	officer: Chief Scientific & Med Officer	338 MAIN STREET #26E, SAN FRANCISCO CA 94105
Eliav Barr	director	C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080